Analysts’ Top Healthcare Picks: Allakos Inc (ALLK), Pieris Pharmaceuticals (PIRS)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allakos Inc (ALLKResearch Report) and Pieris Pharmaceuticals (PIRSResearch Report) with bullish sentiments.

Allakos Inc (ALLK)

In a report issued on August 5, Tim Lugo from William Blair maintained a Buy rating on Allakos Inc. The company’s shares opened today at $84.88, close to its 52-week high of $92.84.

According to TipRanks.com, Lugo is a 4-star analyst with an average return of 10.8% and a 39.0% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, BioMarin Pharmaceutical Inc., and Aclaris Therapeutics Inc.

Allakos Inc has an analyst consensus of Moderate Buy, with a price target consensus of $89.

See today’s analyst top recommended stocks >>

Pieris Pharmaceuticals (PIRS)

In a report issued on August 5, Matt Phipps from William Blair maintained a Buy rating on Pieris Pharmaceuticals. The company’s shares opened today at $5.15.

Phipps wrote:

“Wenzel has extensive experience conducting clinical trials in asthma patients, including as lead author in the Phase II trials of Dupixent (Wenzel et al., 2016) and co-author in the Phase III trials. For additional background on PRS-060 and FeNO biology , see our recent note, at ERS With Promising Clinical Profile.”

According to TipRanks.com, Phipps has currently no stars on a ranking scale of 0-5 stars, with an average return of -23.9% and a 33.3% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics Plc, Kezar Life Sciences Inc, and Atara Biotherapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pieris Pharmaceuticals with a $6 average price target, a 16.5% upside from current levels. In a report issued on August 2, Cowen & Co. also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.